[Analysis on trends of mortality rate and disease burden of liver cancer in Tianjin, China from 1999 to 2021].

Zhonghua Zhong Liu Za Zhi

Department of Vital Statistics, Institution of Non-Communicable Disease Control and Prevention, Tianjin Centers for Diseases Control and Prevention, Tianjin300011,China.

Published: November 2024

To explore the trends and distribution of liver cancer between sexes, ages, and urban-rural areas in Tianjin, China from 1999 to 2021, and provide data for targeted prevention and control strategies of liver cancer in Tianjin. Liver cancer mortality data of Tianjin during 1999-2021 were from the Tianjin population based mortality surveillance system maintained by the Tianjin Centers for Disease Control and Prevention (CDC), and the population data of permanent Tianjin residents were from Tianjin Municipal Public Security Bureau. Liver cancer mortality, years of life lost (YLL), years lived with disability (YLD), and disability adjusted life years (DALY) were calculated using the cause of death surveillance data collected by Tianjin Centers for Disease Control and Prevention. The distributions of these data among residents of different sexes, ages, and regions were analyzed. Segi's world standard population was used for standardization. Joinpoint regression was used for trend analysis on the mortality rate of liver cancer and the disease burden. The liver cancer mortality rate in Tianjin decreased by 46.75% from 1999 to 2021, with distinct phased characteristics. From 1999 to 2010, the age-sex-standardized mortality rate (SMR) decreased from 12.62/100 000 to 11.64/100 000 with an annual percent change (APC) of -1.32% (=0.003). From 2010 to 2021, the SMR decreased from 11.64/100 000 to 6.72/100 000 (APC=-3.89%, <0.001). The age-sex-standardized DALY rates(SDR) decreased by 50.63% from 1999 to 2021, also with distinct phased characteristics. From 1999 to 2010, the SDR decreased from 388.67/100 000 to 349.38/100 000 (APC=-1.35%, =0.002). From 2010 to 2021, the SDR decreased from 349.38/100 000 to 191.88/100 000 (APC=-4.43%, <0.001). The liver cancer mortality rate declined most rapidly in the age group under 45 years; the APC for those under 35 years was -5.07% (<0.001), and for those aged 35-44 years, the APC was 0.63% (=0.707) and -8.21% (<0.001) before and after 2007, respectively. Both SMR and SDR were significantly higher in males than in females (<0.01). Both SMR and SDR were significantly higher in urban areas than in rural areas from 1999 to 2007 (<0.05), but they became similar after 2008. Liver cancer DALY are predominantly YLL, accounting for 99%. The median age of liver cancer deaths in Tianjin during 1999-2021 was 64-68 years old, with males lower than females (<0.05), and rural areas lower than urban areas (<0.05), generally showing an increasing trend (1999-2014: APC=0.11%, =0.047; 2014-2021: APC=0.51%, =0.005). Liver cancer mortality rate and disease burden decreased from 1999 to 2021 in Tianjin, with an especially accelerated decline after 2010. Further efforts to reduce liver cancer mortality in Tianjin are needed, and special attention should be focused on the elderly, male, and rural residents.

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112152-20240101-00001DOI Listing

Publication Analysis

Top Keywords

liver cancer
48
mortality rate
24
cancer mortality
24
1999 2021
16
tianjin
13
disease burden
12
liver
12
cancer
12
mortality
10
rate disease
8

Similar Publications

Apatinib, a commonly used tyrosine kinase inhibitor in cancer treatment, can cause adverse reactions such as hypertension. Hypertension, in turn, can increase the risk of certain cancers. The coexistence of these diseases makes the use of combination drugs more common in clinical practice, but the potential interactions and regulatory mechanisms in these drug combinations are poorly understood.

View Article and Find Full Text PDF

Background: Nanoparticles of zinc oxide (ZnO-NPs) are frequently implemented in cosmetics, additives, and electronic devices. Moreover, their applications extend to water treatment, drug delivery, and cancer therapy. As a result, NP toxicity became an essential subject in biosafety research.

View Article and Find Full Text PDF

Current status of drug therapy for chronic hepatitis B.

World J Gastroenterol

January 2025

Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma.

View Article and Find Full Text PDF

Background: Colorectal polyps are commonly observed in patients with chronic liver disease (CLD) and pose a significant clinical concern because of their potential for malignancy.

Aim: To explore the clinical characteristics of colorectal polyps in patients with CLD, a nomogram was established to predict the presence of adenomatous polyps (AP).

Methods: Patients with CLD who underwent colonoscopy at Tianjin Second People's Hospital from January 2020 to May 2023 were evaluated.

View Article and Find Full Text PDF

Background: Focal nodular hyperplasia (FNH)-like lesions are hyperplastic formations in patients with micronodular cirrhosis and a history of alcohol abuse. Although pathologically similar to hepatocellular carcinoma (HCC) lesions, they are benign. As such, it is important to develop methods to distinguish between FNH-like lesions and HCC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!